Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7907.016 | 1.1895 | 1.2823 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7907.016 | 0.8685 | 0.7967 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7907.016 | 1.1325 | 1.1985 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7907.016 | 1.1128 | 1.1694 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7907.016 | 1.0975 | 1.1467 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7907.016 | 0.9802 | 0.9698 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7907.016 | 0.9544 | 0.9303 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7907.016 | 0.4523 | 0.0938 | 1.3145 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7909.016 | 0.9472 | 0.9224 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7909.016 | 1.2351 | 1.3332 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7909.016 | 0.8324 | 0.7494 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7909.016 | 1.0515 | 1.0746 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7909.016 | 1.1370 | 1.1965 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7909.016 | 1.1207 | 1.1734 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7909.016 | 1.0088 | 1.0129 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7909.016 | 1.1446 | 1.2072 | 1.3701 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7909.016 | 0.5387 | 0.2734 | 1.3701 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7912.016 | 0.9492 | 0.7734 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7912.016 | 0.9418 | 0.7419 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7912.016 | 0.9422 | 0.7436 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7912.016 | 0.9587 | 0.8144 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7912.016 | 0.8571 | 0.4017 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 7912.016 | 0.9122 | 0.6182 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7912.016 | 0.7890 | 0.1580 | 0.4337 | |
| SK-BR-3 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7912.016 | 0.4946 | -0.6055 | 0.4337 |